- Home
- SISI vs SNOA Comparison
SISI vs SNOA Comparison
Compare SISI & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- SNOA
- Stock Information
- Founded
- SISI 1997
- SNOA 1999
- Country
- SISI China
- SNOA United States
- Employees
- SISI N/A
- SNOA N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- SNOA Health Care
- Exchange
- SISI Nasdaq
- SNOA Nasdaq
- Market Cap
- SISI 6.5M
- SNOA 6.4M
- IPO Year
- SISI 2016
- SNOA 2007
- Fundamental
- Price
- SISI $5.33
- SNOA $3.05
- Analyst Decision
- SISI
- SNOA
- Analyst Count
- SISI 0
- SNOA 0
- Target Price
- SISI N/A
- SNOA N/A
- AVG Volume (30 Days)
- SISI 279.7K
- SNOA 54.8K
- Earning Date
- SISI 09-29-2025
- SNOA 08-07-2025
- Dividend Yield
- SISI N/A
- SNOA N/A
- EPS Growth
- SISI N/A
- SNOA N/A
- EPS
- SISI N/A
- SNOA N/A
- Revenue
- SISI $9,601,324.00
- SNOA $14,912,000.00
- Revenue This Year
- SISI N/A
- SNOA $23.00
- Revenue Next Year
- SISI N/A
- SNOA $24.59
- P/E Ratio
- SISI N/A
- SNOA N/A
- Revenue Growth
- SISI 1133.26
- SNOA 17.43
- 52 Week Low
- SISI $4.71
- SNOA $1.75
- 52 Week High
- SISI $852.00
- SNOA $5.93
- Technical
- Relative Strength Index (RSI)
- SISI 30.48
- SNOA 44.07
- Support Level
- SISI $6.10
- SNOA $2.91
- Resistance Level
- SISI $7.15
- SNOA $3.16
- Average True Range (ATR)
- SISI 1.21
- SNOA 0.21
- MACD
- SISI 0.06
- SNOA -0.03
- Stochastic Oscillator
- SISI 0.34
- SNOA 29.30
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.